Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03583710 · ClinicalTrials.gov registry record · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
A Phase 3 study of ENSAT Stage I Adrenal Cortex Carcinoma and ENSAT Stage II Adrenal Cortex Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT03583710 is a Phase 3 study of ENSAT Stage I Adrenal Cortex Carcinoma and ENSAT Stage II Adrenal Cortex Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 240 participants. The trial reports 20 study locations across 4 states.
The verdict
NCT03583710, a Phase 3 study of ENSAT Stage I Adrenal Cortex Carcinoma and ENSAT Stage II Adrenal Cortex Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial studies how well mitotane alone works compared to mitotane with cisplatin and etoposide when given after surgery in treating patients with adrenocortical cancer that has a high risk of coming back (recurrence). Cortisol can cause the growth of adrenocortical tumor cells. Antihormone therapy, such as mitotane, may lessen the amount of cortisol made by the body. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether mitotane alone or mitotane with cisplatin and etoposide after surgery works better in treating patients with adrenocortical carcinoma.
Conditions Studied
Interventions
- DRUG Cisplatin
- OTHER Quality-of-Life Assessment
- DRUG Etoposide
- DRUG Mitotane
Study Locations (20)
Other
- Institut de Cancérologie de l'Ouest (ICO) - Angers
- CHU Angers, Hôpital Larrey - Angers
- CHU Besançon, Hôpital Jean Minjoz - Besançon
- CHU Brest, Hôpital La Cavale Blanche - Brest
- Centre Georges François Leclerc - Dijon
- HCL Hôpital Louis Pradel - Lyon
- CHU Nantes, Hôpital René et Guillaume Laënnec - Nantes
- CHU Nantes, Hôpital René et Guillaume Laënnec - Nantes
- Hôpital Cochin, AP-HP - Paris
- Hôpital Cochin, AP-HP - Paris
- CHU Bordeaux - Hôpital Haut Lévèque - Pessac
- CHU Poitiers - Poitiers
- CHU Reims - Reims
- HUS, Hôpital Hautepierre - Strasbourg
- ICANS Institut de cancérologie Strasbourg Europe - Strasbourg
- CHU Toulouse, Hôpital Larrey - Toulouse
- CHU Toulouse, Hôpital Rangueil - Toulouse
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Missouri
- Siteman Cancer Center at Washington University - St Louis
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2018-08-20 |
| Est. Completion | 2029-01-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03583710
The ClinicalTrials.gov registry entry for NCT03583710 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with ENSAT Stage I Adrenal Cortex Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Cisplatin is the first listed.
NCT03583710 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, Michigan, Missouri.
Frequently Asked Questions
What is clinical trial NCT03583710 about?
NCT03583710 is a clinical study titled "Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence". This phase III trial studies how well mitotane alone works compared to mitotane with cisplatin and etoposide when given after surgery in treating patients with adrenocortical cancer that has a high risk of coming back (recurrence). Cortisol can cause the growth of adrenocortical tumor cells. Antihor...
What is the current status of trial NCT03583710?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2018-08-20. Estimated completion is 2029-01-01.
What conditions does trial NCT03583710 study?
This clinical trial studies the following conditions: ENSAT Stage I Adrenal Cortex Carcinoma, ENSAT Stage II Adrenal Cortex Carcinoma, ENSAT Stage III Adrenal Cortex Carcinoma.
What interventions are being tested in trial NCT03583710?
The interventions under investigation include: Cisplatin (DRUG), Quality-of-Life Assessment (OTHER), Etoposide (DRUG), Mitotane (DRUG).
Who is sponsoring clinical trial NCT03583710?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03583710 being conducted?
This trial has 20 study locations across Michigan, Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
ENSAT Stage I Adrenal Cortex Carcinoma
All registered trials for this condition
ENSAT Stage II Adrenal Cortex Carcinoma
All registered trials for this condition
Michigan
All trials with a study site in Michigan
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.